Smart living with a dumb pancreas.

Visit Diabetes Notes

Byetta on the wrong end of pancreatitis claims

Posted on August 19, 2008

A new class of diabetes drugs, tipped to rake in billions of dollars, faces an uncertain future following six cases of severe pancreas inflammation linked to Amylin and Eli Lilly s Byetta. So-called GLP-1 drugs like Byetta and similar products being developed by firms including Novo Nordisk and Roche are seen as a promising new way to fight the growing problem of diabetes, which is closely linked to obesity.This is the first I have heard of these concerns. Byetta is a drug used to treat type 2 diabetes and is also known to help persons shed a lot of pounds. I feared this when Byetta...

Original article link


diabetes , obesity , type 2 diabetes , weight loss